GLP-1 Medicines in Australia (2026): TGA Approval, PBS Access and Safety Updates

Which GLP-1 medicines are used in Australia? The TGA class summary names semaglutide (Ozempic and Wegovy), liraglutide (Victoza and Saxenda) and dulaglutide (Trulicity), plus the dual GIP/GLP-1 agonist tirzepatide (Mounjaro). Their approved uses differ. TGA registration, PBAC recommendation, PBS subsidy and local stock are separate questions.

This guide separates registration, indication and subsidy for GLP-1 and related incretin medicines in Australia. The comparison below was source-checked on 20 October 2026; each authority record retains its own stated date.

GLP-1 medicines in Australia: the short answer

TGA registration, approved indication, PBAC recommendation and an active PBS listing are separate decisions. The comparison below was checked against official sources on 20 October 2026. The PBS records and A–Z listings inspected identify their information as current to 1 October 2026.

The Wegovy MASH extension registered on 30 March 2026 covers non-cirrhotic MASH with moderate to advanced fibrosis in adults. This indication has provisional approval dependent on confirmatory evidence; it is not a PBS funding decision.

Verification trail: TGA class summary; PBS T medicine listing, M brand listing and W brand listing. Absence statements are limited to those dated records and must be checked again when they change.

For the other marketed agents, the TGA summary describes Trulicity and Victoza for type 2 diabetes and Saxenda for chronic weight management. Read the Wegovy PBS chronology, Mounjaro status guide and regulatory-system comparison for distinct questions.

Choose the exact Australian guide

These pages answer distinct intents. This hub remains the cross-brand comparison; the dedicated guides provide dated evidence trails for each high-change question.

Start with the exact question

This sequence prevents the most common search-result error: treating TGA approved, PBAC recommended, PBS listed, available and clinically studied as synonyms. For a complete explanation, use our TGA vs ARTG vs PBAC vs PBS guide.

Five different questions are often collapsed into “Is it approved?”

1. Is the medicine on the ARTG?

ARTG inclusion is the starting point for lawful routine supply of a therapeutic good in Australia. The register can be searched by product name, active ingredient, sponsor or ARTG identifier. A similar-sounding online product, compounded preparation or imported vial is not automatically covered by the registration of a branded medicine.

2. What indication did the TGA approve?

Approval is indication-specific. Ozempic and Wegovy both contain semaglutide, but the TGA describes Ozempic as a type 2 diabetes medicine and Wegovy as a chronic weight-management medicine. A molecule, brand and approved use must be read together.

3. Has PBAC recommended PBS listing?

PBAC evaluates clinical effectiveness, safety and cost-effectiveness for the population proposed by the sponsor. A positive recommendation is an important step, but it is not the final listing. The requested population can also be much narrower than the full TGA-approved indication.

4. Is it actually listed on the PBS today?

After a recommendation, pricing, financial arrangements, government approval and prescribing-system changes may still be required. The Wegovy status record illustrates the difference: PBAC recommended a listing for people with established cardiovascular disease and obesity under specified circumstances, yet the official record stated that listing had not occurred as of 1 October 2026.

5. Is it currently available?

Registration and subsidy do not guarantee supply at every pharmacy. Shortages, distribution constraints and local stock can change. The PBS obesity-access page reported no Australian GLP-1 shortage as of February 2026, but the TGA shortages database remains the appropriate live source.

What “Ozempic on the PBS” does and does not mean

Ozempic is PBS-listed for eligible people with type 2 diabetes under its restriction. That does not create a general PBS entitlement for weight loss. Search results and social posts often erase the condition attached to a listing; the condition is the essential part.

Likewise, a private prescription does not mean a medicine is PBS-subsidised, and a PBAC recommendation does not mean a medicine is already available at the PBS co-payment. Readers should verify the active restriction on the PBS website rather than rely on an old headline.

Wegovy PBS status: recommended is not yet listed

In November 2025, PBAC recommended semaglutide (Wegovy) for a specified group with established cardiovascular disease and obesity, subject to pricing and risk-sharing arrangements. The official medicine-status record was current to 1 October 2026 and showed that complete documentation had not been accepted, agreement to listing arrangements had not commenced, and PBS listing had not occurred.

This is why “Wegovy approved in Australia”, “Wegovy recommended for PBS listing” and “Wegovy is on the PBS” are not interchangeable statements.

Mounjaro in Australia: dual agonist, two regulatory questions

Mounjaro contains tirzepatide and acts at both GIP and GLP-1 receptors. The TGA describes it as approved for type 2 diabetes and chronic weight management. PBS access must still be checked by indication. The Australian Government’s March 2026 obesity-access advice stated that the tirzepatide sponsor had not submitted for PBS listing for overweight or obesity.

This status is separate from any PBAC consideration for diabetes. A reader searching “Mounjaro PBS Australia” should always check which condition, patient group and date a result refers to.

Safety information changed during 2025–2026

Delayed gastric emptying and procedures

In June 2025, the TGA said Product Information and Consumer Medicine Information documents were being updated with a warning about pulmonary aspiration during general anaesthesia or deep sedation. GLP-1 and dual GIP/GLP-1 medicines can delay gastric emptying, so the TGA advised patients to tell relevant health professionals that they use one of these medicines before a procedure.

Rare but severe eye disorder warning

On 23 July 2026, the TGA announced class-wide warning updates concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare disorder that can cause permanent visual impairment. The TGA advised prompt medical attention for sudden vision loss. The complete wording and consumer advice are in the TGA safety alert.

Counterfeit and unregistered products

Australian approval of a branded prescription medicine does not validate an unregistered product using the same drug name. In March 2026, TGA testing found imported products labelled as containing GLP-1 that contained no GLP-1 or analogue. In September 2026, the regulator warned about products marketed as retatrutide after testing a vial linked to a serious adverse-event report. Retatrutide remains investigational rather than a marketed Australian GLP-1 medicine.

See the TGA’s counterfeit GLP-1 alert and our source-led retatrutide alert analysis.

A practical verification pathway

1. Identify the exact active ingredient and brand. Similar names do not establish identity.
2. Check the ARTG and Product Information. Confirm the registered product, sponsor and approved indication.
3. Check the current PBS item and restriction. Do not infer subsidy from TGA approval or a PBAC recommendation.
4. Check TGA safety and shortage notices. These may change after registration.
5. For investigational drugs, use the trial registry. A clinical trial is not marketing approval.

Our ARTG and unapproved therapeutic goods guide explains these categories in more detail, while the clinical-trials hub separates registered studies from published results and regulatory decisions.

Frequently asked questions

Are GLP-1 medicines legal in Australia?

Several prescription GLP-1 medicines are registered and marketed in Australia for specific indications. That does not make every product advertised as “GLP-1”, every imported vial or every use lawful or approved. Verify the precise product and indication.

Is Ozempic approved for weight loss in Australia?

The TGA’s class summary describes Ozempic as approved for type 2 diabetes. Wegovy is the semaglutide brand described as approved for chronic weight management. Off-label prescribing questions belong with a qualified prescriber and do not change the registered indication.

Is Wegovy on the PBS?

Not according to the official medicine-status record current to 1 October 2026. PBAC had recommended a restricted listing, but the record said PBS listing had not yet occurred.

Is Mounjaro approved for weight management?

The TGA describes Mounjaro as approved for both type 2 diabetes and chronic weight management. PBS subsidy is a separate question and depends on the indication and current listing.

Is retatrutide an approved GLP-1 medicine?

No. Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist being studied in clinical trials. It should not be grouped with marketed Australian medicines. See our retatrutide evidence and regulatory-status profile.

Looking at oral medicines or emerging targets? The oral GLP-1 evidence tracker distinguishes US FDA decisions from individual trial results; it does not substitute for the Australian records on this page. Our amylin-versus-GLP-1 explainer provides the mechanism and study context for CagriSema and related research.

Reading a liver-specific claim? Our MASH and MASLD drug-evidence tracker separates dated US FDA decisions, liver-biopsy endpoints and confirmatory clinical-outcome questions. Australian registration and PBS decisions remain the separate local records discussed on this page.

Sources and update method

• TGA: medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists
• PBS/PBAC: equitable access to GLP-1 obesity treatments
• PBS Medicine Status: semaglutide (Wegovy)
• TGA: GLP-1 receptor agonists and rare severe eye disorders
• TGA: counterfeit products claiming to contain GLP-1
• PBS semaglutide item 14163K
• TGA Wegovy provisional MASH indication extension
• PBS T medicine listing
• PBS M brand listing
• PBS W brand listing

The approval/subsidy comparison was source-checked on 20 October 2026. Its linked official records retain their own current-to dates. Other sections retain the scope and dates of their cited notices; this edit does not imply a new medical review.